Fan Dong

Fan Dong


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
YLYunpeng Liu
Yunpeng Liu
WHWei He
Wei He
XLXiaoju Li
Xiaoju Li
XLXiyan Lu
Xiyan Lu
CWChihua Wu
Chihua Wu
ZHZhao Huadong
Zhao Huadong
Breast cancer is the most prevalent malignancy worldwide, with approximately 50% of HER2-positive advanced breast cancer patients eventually developing brain metastases, significantly reducing survival. Current HER2-targeted therapies, such as trastuzumab, exhibit limited efficacy in patients with brain metastases due to poor blood-brain barrier penetration and drug resistance. This study aimed to develop a novel strategy for treating HER2-positive breast cancer brain metastases to improve overall survival. We engineered nanoparticles encapsulating circular RNA encoding the chemokine CXCL9 and an anti-PD-1 scFv, designed to target HER2-positive brain metastases. Our results demonstrate that these nanoparticles significantly enhance anti-tumor activity both in vitro and in vivo without exhibiting significant systemic toxicity. This approach improves the local tumor immune microenvironment while inducing lower systemic toxicity. In conclusion, we have established a platform of membrane-encapsulated circular RNA nanoparticles capable of targeting brain tumor lesions, showing potential for application in various brain disorders, including metastatic brain tumors. This novel approach offers a promising strategy for addressing the urgent need for effective treatments for HER2-positive breast cancer brain metastases.

3 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
GLGuodong Li
Guodong Li
SPShuangpeng Pu
Shuangpeng Pu
LYLisiyao You
Lisiyao You
YGYuan Gao
Yuan Gao
YZYuexia Zhong
Yuexia Zhong
XLXiyan Lu
Xiyan Lu
Outer membrane vesicles (OMVs) are double-layered structures of nanoscale lipids released by gram-negative bacteria. They have the same membrane composition and characteristics as primitive cells, which enables them to penetrate cells and tissues efficiently. These OMVs exhibit excellent membrane stability, immunogenicity, safety, and permeability (which makes it easier for them to penetrate into tumour tissue), making them suitable for developing cancer vaccines and drug delivery systems. Recent studies have focused on engineering OMVs to enhance tumour-targeting capabilities, reduce toxicity, and extend circulation time in vivo. This article reviews the latest progress in OMV engineering for tumour treatment and discusses the challenges associated with the use of OMV-based antitumour therapy in clinical practice.

10 February 2025 in BMB Reports
Verified
Journal Article
Open access
PDF file
WHWei He
Wei He
MZMeng Zhang
Meng Zhang
YZYuexia Zhong
Yuexia Zhong
YGYuan Gao
Yuan Gao
FDFan Dong
Fan Dong
XLXiyan Lu
Xiyan Lu
Wei He, Meng Zhang, Yuexia Zhong, Yuan Gao, Dong Fan, Xiyan Lu. BMB Reports -0001;0:. https://doi.org/10.5483/BMBRep.2024-0165